((lp0
VisWord
p1
aVcase
p2
aVstops
p3
aVstem
p4
acnltk.probability
FreqDist
p5
((dp6
S'exploratory investig'
p7
I1
sS'pre-trial antihypertensive treatment dur'
p8
I1
sS'random'
p9
I2
sS'artery diseas'
p10
I1
sS'arm of the antihypertensive tri'
p11
I1
sS'pharmacologic treatment of particip'
p12
I1
sS'for particip'
p13
I1
sS'lipid low'
p14
I1
sS'of functional capac'
p15
I1
sS'coronary angioplasti'
p16
I1
sS'case-fatality for'
p17
I1
sS'post-event use of open-label diuret'
p18
I1
sS'chd event'
p19
I1
sS'high-density lipoprotein'
p20
I1
sS'clinical investig'
p21
I1
sS'chd death'
p22
I3
sS'secondary clinical outcom'
p23
I1
sS'edema'
p24
I2
sS'systolic hypertens'
p25
I1
sS'hg'
p26
I6
sS'cardiovascular caus'
p27
I1
sS'systolic blood'
p28
I1
sS'systolic dysfunct'
p29
I1
sS'continuous vari'
p30
I1
sS'analys'
p31
I1
sS'hf patient'
p32
I2
sS'risk'
p33
I3
sS'heart failure diagnostic criteria'
p34
I1
sS'public health'
p35
I1
sS'chronic obstructive pulmonary diseas'
p36
I1
sS'treatment of particip'
p37
I2
sS'coronary heart diseas'
p38
I1
sS'aventi'
p39
I1
sS'hf event'
p40
I13
sS'new'
p41
I2
sS'classification of functional capac'
p42
I1
sS'dose'
p43
I2
sS'hf diagnosi'
p44
I5
sS'medical management for hf'
p45
I1
sS'hf diagnos'
p46
I1
sS'hf ascertain'
p47
I1
sS'ad hoc'
p48
I1
sS'comparability of baselin'
p49
I1
sS'for diastolic hf'
p50
I2
sS'health quest'
p51
I1
sS'follow-up clin'
p52
I1
sS'hr'
p53
I1
sS'hf incid'
p54
I1
sS'validation of hf'
p55
I1
sS'statist'
p56
I3
sS'dsmb'
p57
I1
sS'cholesterol'
p58
I1
sS'ldl'
p59
I1
sS'prescription of open-label medicin'
p60
I1
sS'total mort'
p61
I1
sS'certif'
p62
I3
sS'clinical diagnos'
p63
I1
sS'doxazosin particip'
p64
I13
sS'revascular'
p65
I2
sS'medical management baselin'
p66
I1
sS'compens'
p67
I1
sS'fatal coronary heart diseas'
p68
I1
sS'nu-pharm'
p69
I1
sS'hospitalization for'
p70
I1
sS'cardiac diseas'
p71
I1
sS'diseas'
p72
I12
sS'pre-trial antihypertensive treat'
p73
I1
sS'fatal coronary heart'
p74
I1
sS'for chd ev'
p75
I2
sS'diastolic dysfunct'
p76
I2
sS'durat'
p77
I1
sS'nonfatal hf ev'
p78
I1
sS'arm'
p79
I3
sS'all-cause mort'
p80
I2
sS'clinic visit'
p81
I1
sS'the primary endpoint'
p82
I1
sS'compar'
p83
I2
sS'of chlorthalidon'
p84
I2
sS'ldl cholesterol'
p85
I1
sS'jtw'
p86
I1
sS'particip'
p87
I49
sS'systol'
p88
I1
sS'ventricular hypertrophi'
p89
I3
sS'non-hospitalized particip'
p90
I1
sS'pulmonary diseas'
p91
I2
sS'cardiovascular risk'
p92
I1
sS'staff'
p93
I2
sS'outpatient revascular'
p94
I2
sS'fatal ev'
p95
I1
sS'altern'
p96
I1
sS'documentation for qu'
p97
I1
sS'treatments for hf'
p98
I1
sS'patholog'
p99
I1
sS'heart classification functional class iii'
p100
I2
sS'national heart'
p101
I2
sS'ace-inhibitor'
p102
I8
sS'protocol-defined secondary clinical outcom'
p103
I1
sS'non-hospitalized hf'
p104
I1
sS'time-from-event-to-death analyses of particip'
p105
I1
sS'hypertensive particip'
p106
I1
sS'alternative antihypertensive drug'
p107
I1
sS'noninvas'
p108
I1
sS'post-hf event medical manag'
p109
I1
sS'statu'
p110
I3
sS'chlorthalidone for'
p111
I1
sS'hoc committe'
p112
I1
sS'randomization visit'
p113
I1
sS'drug'
p114
I7
sS'lvh'
p115
I3
sS'guidelin'
p116
I2
sS'trial'
p117
I5
sS'x-ray characteristic of hf'
p118
I1
sS'post-event use of'
p119
I1
sS'committe'
p120
I2
sS'ctc'
p121
I4
sS'studi'
p122
I3
sS'antihypertensive treatment of'
p123
I1
sS'medicin'
p124
I2
sS'lipid lowering treat'
p125
I1
sS'extremity edema'
p126
I1
sS'activ'
p127
I2
sS'sixth'
p128
I1
sS'classif'
p129
I1
sS'angiotensin-converting enzym'
p130
I1
sS'post-hf ev'
p131
I1
sS'allhat'
p132
I15
sS'the chlorthalidon'
p133
I1
sS'allhat manu'
p134
I1
sS'diagnostic standards of th'
p135
I1
sS'jnc vi'
p136
I1
sS'brd'
p137
I1
sS'fatal hf'
p138
I5
sS'novarti'
p139
I1
sS'dyspnea'
p140
I3
sS'fatal chd'
p141
I2
sS'ejection fraction information ascertain'
p142
I1
sS'pp'
p143
I5
sS'heart attack tri'
p144
I1
sS'chd'
p145
I7
sS'antihypertensive treat'
p146
I1
sS'prescript'
p147
I1
sS'visit'
p148
I2
sS'protocol-required document'
p149
I1
sS'risk factor for'
p150
I2
sS'two-third'
p151
I2
sS'two-thirds of'
p152
I1
sS'recommend'
p153
I2
sS'definition of hf'
p154
I1
sS'tachycardia'
p155
I1
sS'glaxo-smithklin'
p156
I1
sS'fraction review'
p157
I1
sS'adequaci'
p158
I1
sS'doxazosin treatment arm'
p159
I1
sS'antihypertensive drug'
p160
I1
sS'king pharmaceut'
p161
I1
sS'medical management baseline characteristics of chlorthalidon'
p162
I1
sS'chest x-ray characteristic of hf'
p163
I1
sS'validation of'
p164
I1
sS'lipid tri'
p165
I1
sS'skb'
p166
I2
sS'diastolic blood'
p167
I1
sS'antihypertensive treatment dur'
p168
I1
sS'allhat event report'
p169
I1
sS'lipoprotein'
p170
I1
sS'sbp'
p171
I2
sS'hf event report'
p172
I1
sS'iii'
p173
I2
sS'document'
p174
I9
sS'lung diseas'
p175
I1
sS'solvay'
p176
I1
sS'physician'
p177
I1
sS'classification of'
p178
I1
sS'endpoint'
p179
I10
sS'baseline characteristics of chlorthalidon'
p180
I1
sS'ejection fraction review'
p181
I1
sS'sixth report'
p182
I1
sS'non-cardiac caus'
p183
I1
sS'allhat endpoint'
p184
I2
sS'medication adher'
p185
I1
sS'calcium-channel block'
p186
I1
sS'mi'
p187
I2
sS'baseline characteristics baselin'
p188
I1
sS'treatments for'
p189
I1
sS'astrazeneca'
p190
I1
sS'outcom'
p191
I3
sS'bm'
p192
I5
sS'asymptomatic hypertens'
p193
I1
sS'cvd'
p194
I2
sS'hdl'
p195
I2
sS'documentation for'
p196
I1
sS'hypertrophi'
p197
I3
sS'hf outcom'
p198
I4
sS'heart'
p199
I7
sS'routine endpoints subcommitte'
p200
I1
sS'new york heart classification functional class'
p201
I2
sS'hospital discharg'
p202
I1
sS'routine endpoint'
p203
I1
sS'allhat criteria for hf'
p204
I1
sS'chlorthalidon'
p205
I11
sS'ordinary physical act'
p206
I1
sS'pharmacologic treatment of'
p207
I1
sS'upjohn'
p208
I1
sS'sankyo'
p209
I1
sS'in-hospit'
p210
I1
sS'event document'
p211
I2
sS'routine endpoints subcommittee qu'
p212
I1
sS'grant'
p213
I1
sS'ankle edema'
p214
I1
sS'medic'
p215
I3
sS'open-label beta-block'
p216
I1
sS'pharmacologic treat'
p217
I1
sS'chest x-ray'
p218
I1
sS'medical manag'
p219
I3
sS'coronary arteri'
p220
I1
sS'invasive tool'
p221
I1
sS'clinical outcom'
p222
I1
sS'bristol-my'
p223
I1
sS'monarch'
p224
I1
sS'hypertens'
p225
I2
sS'lowering treat'
p226
I1
sS'fraction information ascertain'
p227
I1
sS'alpha-adrenergic block'
p228
I1
sS'doxazosin arm'
p229
I3
sS'evid'
p230
I1
sS'two-thirds of ejection fract'
p231
I1
sS'allhat definition of hf'
p232
I1
sS'blood'
p233
I1
sS'risk factor for chd ev'
p234
I1
sS'catheter'
p235
I1
sS'time-from-event-to-death analyses of'
p236
I1
sS'phu'
p237
I5
sS'hypercholesterolemic pati'
p238
I1
sS'sy'
p239
I2
sS'appropri'
p240
I1
sS'of clinical ev'
p241
I1
sS'heart attack'
p242
I1
sS'sv'
p243
I2
sS'ambigu'
p244
I1
sS'caus'
p245
I4
sS'attack tri'
p246
I1
sS'gsk'
p247
I2
sS'allhat clinical tri'
p248
I1
sS'non-medical staff'
p249
I1
sS'se'
p250
I2
sS'clinical ev'
p251
I2
sS'st-t wave'
p252
I1
sS'allhat criteria for'
p253
I1
sS'risk factor for chd'
p254
I1
sS'categorical vari'
p255
I1
sS'probability of doxazosin showing benefit'
p256
I1
sS'diagnos'
p257
I2
sS'blocker'
p258
I2
sS'pharmacia'
p259
I1
sS'of hf diagnosi'
p260
I1
sS'jnc'
p261
I1
sS'report'
p262
I4
sS'lipid'
p263
I1
sS'pharmacologic manag'
p264
I1
sS'ad'
p265
I1
sS'for the primary endpoint'
p266
I1
sS'heart failure diagnost'
p267
I1
sS'monitoring board'
p268
I1
sS'death'
p269
I7
sS'monitor'
p270
I1
sS'validation of hf diagnosi'
p271
I1
sS'character'
p272
I1
sS'dysfunct'
p273
I4
sS'hf medic'
p274
I1
sS'characterization of'
p275
I1
sS'exercis'
p276
I1
sS'ventricular dysfunct'
p277
I1
sS'beta-block'
p278
I7
sS'hf particip'
p279
I2
sS'hospitalization for hf'
p280
I1
sS'ejection fract'
p281
I10
sS'baseline eligibility risk'
p282
I1
sS'diagnostic valid'
p283
I1
sS'relative risk of'
p284
I1
sS'open-label drug'
p285
I1
sS'treatment arm of the antihypertensive tri'
p286
I1
sS'nation'
p287
I3
sS'doxazosin treat'
p288
I2
sS'coronary artery diseas'
p289
I1
sS'discharg'
p290
I2
sS'bv'
p291
I1
sS'hg for'
p292
I1
sS'ljh'
p293
I1
sS'chlorthalidone for the primary endpoint'
p294
I1
sS'clinical pictur'
p295
I1
sS'atherosclerotic cardiovascular diseas'
p296
I3
sS'site staff'
p297
I1
sS'obstructive pulmonary diseas'
p298
I1
sS'post-hospit'
p299
I1
sS'total dos'
p300
I1
sS'manual'
p301
I1
sS'manifest'
p302
I1
sS'princip'
p303
I1
sS'allhat clin'
p304
I1
sS'mm hg'
p305
I3
sS'risk of hf'
p306
I1
sS'of particip'
p307
I3
sS'manag'
p308
I2
sS'cumulative ev'
p309
I1
sS'subset'
p310
I1
sS'chlorthalidone treat'
p311
I3
sS'allhat definit'
p312
I1
sS'of doxazosin'
p313
I2
sS'cabg'
p314
I3
sS'searl'
p315
I1
sS'antihypertens'
p316
I1
sS'shep'
p317
I1
sS'nhlbi'
p318
I1
sS'doxazosin'
p319
I8
sS'event'
p320
I20
sS'of the antihypertensive tri'
p321
I1
sS'baselin'
p322
I6
sS'variabl'
p323
I2
sS'affili'
p324
I1
sS'secondary endpoint'
p325
I2
sS'ecg abnorm'
p326
I1
sS'rr'
p327
I4
sS'post-ev'
p328
I2
sS'doxazosin treatment arm of'
p329
I1
sS'non-hospit'
p330
I1
sS'of open-label medicin'
p331
I1
sS'research'
p332
I1
sS'of doxazosin showing benefit'
p333
I1
sS'research gr'
p334
I1
sS'baseline pp'
p335
I2
sS'doxazosin showing benefit'
p336
I1
sS'atenolol'
p337
I1
sS'peripheral arterial diseas'
p338
I2
sS'smithkline beecham'
p339
I1
sS'open-label medicin'
p340
I2
sS'ecg'
p341
I2
sS'comparability of'
p342
I1
sS'of hf'
p343
I5
sS'time-from-event-to-death analys'
p344
I1
sS'clinical diagnosi'
p345
I1
sS'national committe'
p346
I1
sS'hf'
p347
I87
sS'ctc physician'
p348
I1
sS'validation exercis'
p349
I1
sS'ascertain'
p350
I3
sS'baseline sbp'
p351
I1
sS'death certif'
p352
I3
sS'allhat diagnostic criteria'
p353
I1
sS'criteria for hf'
p354
I1
sS'bp'
p355
I1
sS'benefit'
p356
I2
sS'investig'
p357
I2
sS'abbott'
p358
I1
sS'relative risk'
p359
I1
sS'fhhl'
p360
I1
sS'prescription of'
p361
I1
sS'diastolic hf'
p362
I1
sS'aha med'
p363
I1
sS'ace'
p364
I1
sS'pfizer'
p365
I1
sS'hg for th'
p366
I1
sS'quality control evalu'
p367
I1
sS'open-label ace-inhibitor'
p368
I2
sS'doxazosin treatment arm of the antihypertensive tri'
p369
I1
sS'cardiovascular ev'
p370
I1
sS'the antihypertensive tri'
p371
I1
sS'baseline characteristics of'
p372
I1
sS'mortal'
p373
I4
sS'event ascertain'
p374
I1
sS'baseline puls'
p375
I1
sS'squibb'
p376
I1
sS'for hf'
p377
I3
sS'primary endpoint'
p378
I4
sS'vi'
p379
I1
sS'aha'
p380
I1
sS'confirmatory ev'
p381
I1
sS'probability of'
p382
I1
sS'qualiti'
p383
I1
sS'diagnostic criteria'
p384
I3
sS'assess'
p385
I2
sS'clinical site staff'
p386
I1
sS'high-risk hypertensive particip'
p387
I1
sS'lung'
p388
I1
sS'class iii'
p389
I4
sS'statistical analys'
p390
I1
sS'bristol-myers squibb'
p391
I1
sS'treatment dur'
p392
I1
sS'management baseline characteristics of chlorthalidon'
p393
I1
sS'diuret'
p394
I8
sS'physical act'
p395
I2
sS'allhat criteria'
p396
I2
sS'outcome statu'
p397
I1
sS'pictur'
p398
I1
sS'question'
p399
I2
sS'capac'
p400
I2
sS'alternative antihypertens'
p401
I1
sS'confirmatory event document'
p402
I1
sS'ad hoc committe'
p403
I1
sS'new york'
p404
I2
sS'new york heart classification functional class iii'
p405
I2
sS'fraction'
p406
I6
sS'york heart classification functional class iii'
p407
I2
sS'of ejection fract'
p408
I1
sS'arterial diseas'
p409
I2
sS'adher'
p410
I1
sS'clinical sit'
p411
I1
sS'copd'
p412
I1
sS'open-label diuret'
p413
I5
sS'beecham'
p414
I1
sS'nonfatal hf'
p415
I2
sS'criteria'
p416
I4
sS'characterization of clinical ev'
p417
I1
sS'echocardiogram'
p418
I3
sS'new york heart classif'
p419
I2
sS'public health quest'
p420
I1
sS'consult'
p421
I1
sS'risk factor for diastolic hf'
p422
I1
sS'patient'
p423
I3
sS'cardiovascular diseas'
p424
I4
sS'heart failure diagnosi'
p425
I1
sS'heart diseas'
p426
I1
sS'symptom'
p427
I3
sS'chest x-ray characteristic of'
p428
I1
sS'king'
p429
I1
sS'two-component clinical tri'
p430
I1
sS'of open-label diuret'
p431
I2
sS'hg for the chlorthalidon'
p432
I1
sS'beta-blocker use post-ev'
p433
I1
sS'diagnostic standards of'
p434
I1
sS'open-label beta-blocker use post-ev'
p435
I1
sS'minut'
p436
I1
sS'medical management for'
p437
I1
sS'x-ray'
p438
I1
sS'antihypertensive treatment of particip'
p439
I1
sS'chlorthalidone for th'
p440
I1
sS'ab'
p441
I2
sS'biovail'
p442
I1
sS'evalu'
p443
I2
sS'hf outcome statu'
p444
I1
sS'antihypertensive tri'
p445
I1
sS'diagnosi'
p446
I8
sS'chlorthalidone particip'
p447
I7
sS'expir'
p448
I1
sS'angioplasti'
p449
I1
sS'case-fatality for particip'
p450
I1
sS'event report'
p451
I3
sS'az'
p452
I3
sS'for the chlorthalidon'
p453
I1
sS'clinical tri'
p454
I2
sS'probabl'
p455
I1
sS'double-blind'
p456
I1
sS'maximum dos'
p457
I1
sS'allhat ev'
p458
I2
sS'treatment'
p459
I12
sS'medical management baseline characteristics of'
p460
I1
sS'accuraci'
p461
I1
sS'baseline characteristics of doxazosin'
p462
I1
sS'lost-to-follow-up'
p463
I1
sS'wcc'
p464
I1
sS'valid'
p465
I4
sS'confirmatory evid'
p466
I1
sS'pulmonary patholog'
p467
I1
sS'np'
p468
I1
sS'nonfatal mi'
p469
I2
sS'follow-up clinic visit'
p470
I1
sS'tool'
p471
I1
sS'manifestations of hf'
p472
I1
sS'board'
p473
I1
sS'exertional dyspnea'
p474
I1
sS'principal investig'
p475
I1
sS'manifestations of'
p476
I1
sS'ascvd'
p477
I3
sS'post-diagnosis pharmacologic manag'
p478
I1
sS'study criteria'
p479
I1
sS'new york heart'
p480
I2
sS'eligibility risk'
p481
I2
sS'study guidelin'
p482
I2
sS'classification functional class iii'
p483
I2
sS'doxazosin treatment arm of th'
p484
I1
sS'allhat definition of'
p485
I1
sS'enzym'
p486
I1
sS'diagnostic standard'
p487
I1
sS'analyses of particip'
p488
I1
sS'two-fold'
p489
I1
sS'eject'
p490
I1
sS'util'
p491
I2
sS'relative risk of hf'
p492
I1
sS'hf hospit'
p493
I1
sS'km'
p494
I2
sS'hospit'
p495
I6
sS'abnorm'
p496
I1
sS'event medical manag'
p497
I1
sS'hf statu'
p498
I2
sS'review'
p499
I1
stp500
Rp501
tp502
.